NMDA receptor antagonists and pain relief: A meta-analysis of experimental trials by Thompson, Trevor et al.
NMDA receptor antagonists and pain relief: A meta-analysis of 
experimental trials 
 
Trevor Thompsona, PhD, Fiona Whiterab, MSc, Katy Gallopc, MSc, Nicola Veronesed MD, Marco Solmie MD, 
Paul Newtonf, PhD, Brendon Stubbsgh, PhD 
 
aFaculty of Education and Health, University of Greenwich, London SE9 2UG, UK 
bYork Health Economics Consortium, University of York, York, YO10 5NQ, UK 
cAcaster Lloyd Consulting Ltd, London W2 6LG, UK 
dNational Research Council, Neurosciences Department, Aging Branch, Padova, Italy 
eNeuroscience Centre, University of Padova, Padova, Italy 
fDepartment of Adult Nursing & Paramedic Science, University of Greenwich, London SE9 2UG, UK 
gPhysiotherapy Department, South London and Maudsley NHS Foundation Trust, London SE5 8AZ, UK 
hDepartment of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De 
Crespigny Park, London SE5 8AF, UK 
 
Manuscript Type: Article 
Title character count: 81 
Number of references: 35 
Number of tables: 2 
Number of figures: 4 
 
Word count abstract: 197 
Word count of manuscript: 4,209 
Data supplements 
Dryad review link: https://datadryad.org/review?doi=doi:10.5061/dryad.sm4tj6t 
Table 1 (study characteristics) 
Appendices 2 (search terms), 3 (validity criteria) and 4 (reference list of studies included in 
meta-analysis). 
 
 
Corresponding Author: 
Dr Trevor Thompson, t.thompson@gre.ac.uk,  +44 208 3319632 
 
Statistical analysis was performed by the corresponding author.  
THOMPSON   
 
2 
 
Author Disclosures 
 
Dr Thompson, Mrs Whiter, Ms Gallop, Dr Veronese, Dr Solmi, Dr Newton and Dr Stubbs 
report no disclosures.  
 
Funding 
This study was funded by an internal grant awarded to the first author by the University of 
Greenwich. 
  
THOMPSON   
 
3 
 
ABSTRACT 
OBJECTIVES: We conducted a meta-analysis of controlled trials that used experimental 
models of acute pain and hyperalgesia to examine the analgesic effects of N-methyl-D-
aspartate receptor (NMDAR) antagonists. METHODS: Six major databases were 
systematically searched (to 03/2018) for studies using human evoked pain models to 
compare NMDAR antagonists with no-intervention controls. Pain outcome data were 
analyzed with random-effects meta-analysis. RESULTS: Searches identified 70 eligible trials 
(N=1069). Meta-analysis found that low-dose ketamine (<1 mg/kg) produced a decrease in 
the size of hyperalgesic area (Standardized Mean Difference=0.54, CI95[0.34, 0.74], p<.001), 
and a 1.2-point decrease (CI95[0.88, 1.44], p<.001) in pain ratings from 4.6 to 3.4 on a 0-10 
scale (a 26% reduction). Similar analgesia was observed for acute and hyperalgesic models 
and was constant across the dosing range (0.03-1.00 mg/kg). Moderate-high variability in 
effect size was observed and mild side effects (e.g. sedation, sensory disturbance) were 
common. No effects of dextromethorphan were found. CONCLUSIONS: Findings provide 
robust evidence for analgesic and anti-hyperalgesic effects of ketamine, supporting its 
utility for acute and chronic pain management. However, pain relief was modest, 
suggesting ketamine may potentially be most useful when opioids are contraindicated, 
rapid analgesia is required or for pain resistant to conventional medication.  
Keywords: pain, NMDA, ketamine, dextromethorphan, analgesia, review, meta-analysis 
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INTRODUCTION 
Unsatisfactory pain relief from traditional pain medication and the ongoing opioid crisis 
have created an urgent need for alternative analgesics19. N-methyl-D-aspartate receptor 
(NMDAR) antagonists such as ketamine have experienced a surge of renewed clinical and 
research interest in subanesthetic doses (<1mg/kg) for pain treatment, leading to recent 
consensus guidelines on the best usage of ketamine for pain6. Several analgesic 
mechanisms of NMDAR antagonists have been suggested25, with a key candidate the 
reversal of central sensitization believed to be a fundamental component of chronic pain. 
Clinical data are consistent with analgesic benefits of NMDAR antagonists for neuropathic 
pain1, CRPS1,8, acute pain in the emergency room15, and a reduced requirement for opiods4. 
 
However, conclusions on efficacy of NMDAR antagonists are based on heterogenous clinical 
data often of low-grade evidence6,17. To circumvent the methodological issues associated 
with clinical data, experimental pain models have also been employed. These replicate key 
pathological features of acute and chronic hyperalgesic pain states5 in healthy people, and 
can provide insights into analgesic strength, dose-response effects and potential 
mechanisms. However, the use of small samples (typically 10-12 participants) and 
methodological (e.g. dosage) variation across experimental studies have prevented a clear 
overall picture of the analgesic benefits of NMDAR antagonists or a consensus on optimal 
dosages6.  
 
We conducted a meta-analysis of controlled experimental pain trials of NMDAR antagonists 
in healthy participants to: (1) estimate the magnitude of pain relief; (2) estimate a dose-
response relationship, to facilitate identification of the lowest meaningful analgesic dose; 
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(3) establish the most efficacious NMDAR antagonists; and (4) compare analgesic effects for 
acute and hyperalgesic states. 
METHOD 
This meta-analysis was conducted following an a priori but unpublished protocol (available 
upon request), based on PRISMA-P 2015 guidelines18. 
Eligibility Criteria 
Inclusion criteria were the use of: (1) an NMDAR antagonist; (2) a no-intervention control; 
(3) an experimental pain stimulus and quantitative pain assessment; (4) healthy 
participants free from chronic pain. Exclusion criteria were co-administration of other pain 
interventions, drugs with only secondary effects on NMDARs (e.g. methadone) or NMDAR 
antagonists not available as experimental drugs or approved clinical medications. 
Search Strategy 
PubMed, Embase, CENTRAL, CINAHL, PsycINFO and Web of Science databases were 
independently searched (to 19-03-2018) by two reviewers (FW, KG). Search strings 
consisted of terms relating to NMDA AND pain AND noxious experimental stimuli 
(Appendix 2, available from Dryad: https://doi.org/10.5061/dryad.sm4tj6tX). No language 
restrictions were imposed, but animal studies were excluded. Searches were augmented 
through manual searching of reference lists of included articles. 
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Study selection 
Two reviewers (FW, KG) independently screened titles/abstracts, with the full-text of 
potentially eligible articles then examined to reach a final list of articles to be included in 
the meta-analysis. Any disagreements were resolved through discussion with a third 
reviewer (TT). Where necessary, corresponding authors were contacted for more 
information with an initial and, if needed, follow-up email request over a six-week period. 
Of 4 author groups contacted, 1 reply was received. 
Outcomes 
Primary outcomes were: (1) pain ratings, (2) pain tolerance (the point of maximum 
endurance), and (3) size of hyperalgesic area. Secondary outcomes were side effect 
incidence and pain threshold. Threshold was designated as a secondary outcome, as it 
refers to minimum pain and is therefore of lesser clinical relevance. 
Moderators 
Primary moderators were: (1) NMDAR antagonist type and dosage, and (2) hyperalgesic vs. 
acute pain (with no hyperalgesic induction) models. We included (1), as dosage and 
differing receptor affinities across antagonists16 should influence pain response. We 
included (2), as this should provide insights into mechanisms of actions (e.g., whether 
analgesic mechanisms are primarily anti-hyperalgesic or also modulate acute pain).  
 
Secondary moderators were examined to provide preliminary data on drug timing 
(before/during stimulation), noxious stimulus type, study biological sex composition, 
THOMPSON   
 
7 
testing site (upper/lower body), infusion period (for intravenous studies) and pain duration 
(brief phasic/longer-lasting tonic).  
Quality of evidence 
Two reviewers (FW, TT) independently rated each study on 15-item scale used in our 
previous work28 (Appendix 3, available from Dryad: 
https://doi.org/10.5061/dryad.sm4tj6tX) assessing methodological rigor, selection and 
reporting bias. A third reviewer (BS) was consulted in the event of disagreement. This scale 
was based on items from Cochrane collaboration criteria, PRISMA recommendations and 
PEDro guidelines and adapted from our previous work28 for the current review. 
Standard protocol approvals, registrations, and patient consents 
No additional ethical approval was required for this meta-analysis.  
Data Extraction 
Extraction and coding of study data was performed by two reviewers (FW, TT) on a 
standardized template28. Data extracted were: (1) age, sex and bodyweight; (2) NMDAR 
antagonist type, dosage, delivery method, delivery timing (pre-emptive vs. during pain 
stimulation); (3) study design and control condition (nothing vs. placebo); (4) pain outcome; 
(5) pain induction: method, body site and pain model (hyperalgesic vs. acute nociceptive 
testing). Hyperalgesic pain models were those where noxious stimuli were applied to 
primary (injured area) or secondary (surrounding area) sites following established protocols 
to induce hyperalgesia (e.g. topical capsaicin application for >15 minutes to produce 
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inflammation)12. Acute nociceptive models were those where noxious stimulation was 
applied in the absence of hyperalgesic induction. 
 
When multiple effect sizes were available for a study (e.g. across time points or different 
dosages), all such data were extracted. The following data decisions were also made: (1) for 
intravenous ketamine studies, only pain outcome data collected during the infusion period 
were extracted, due to ketamine’s rapid elimination from the bloodstream24; (2) When 
M/SDs were not reported, effect sizes were calculated from any other data that allowed 
their computation7; (3) for a few studies reporting use of multiple outcomes but only 
providing data for some outcomes, data were extracted for available outcomes, and; (4) 
while NMDA dosage in mg/kg bodyweight was extractable for most studies, (i) 16 studies 
reported total dose only, and (ii) 1 study reported blood plasma. For (i), mg/kg was 
calculated using mean body weight imputed from study sex composition and country35, and 
for (ii) we used published equivalency data for blood plasma2,34. The impact of decision 4 
was assessed with sensitivity analysis. 
Effect size 
The standardized mean difference (SMD) for NMDAR antagonists vs. control was computed 
using Hedges' g formula where .20, .50 and .80 represent small, medium and large effects7. 
When computing variance for crossover designs20, we used r=0.65 as an estimated 
correlation amongst within-trial pain outcomes but assessed alternative correlations in 
sensitivity analysis. Effect size was coded so that positive values indicated drug analgesia. 
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Meta-analysis 
An overall effect size was estimated using a random-effects model based on anticipated 
heterogeneity due to methodological variation. We used the robust variance estimation 
(RVE) method13 which allows for the inclusion of multiple, statistically-dependent effect 
sizes from within a study without requiring (rarely reported) information on correlations 
between outcomes. Instead, effect size dependency is based on a single estimated 
common correlation27 and has shown to produce accurate parameter estimates provided 
adjusted RVE degrees of freedom (df)<4 (which primarily results from low study 
numbers)27. 
Because different NMDAR antagonists may have different effects on pain, we added 
medication type as a moderator in our initial meta-analysis. If effect size differed across 
medication types, we conduct separate analyses for each medication, as a single overall 
effect size based on pooled data may be misleading. 
Meta-regression 
We computed I2 as a measure of effect size inconsistency across studies, and tau (τ2) as a 
measure of heterogeneity (twice the value of tau above and below the summary estimate 
gives the estimated 95% range of effects in the population)7. If I2>50%7, RVE meta-
regression was performed to identify potential effect modifiers. For moderators that were 
categorical, these were dummy-coded (omitting any categories with <5 studies), with two 
different model parameterizations used to obtain comparisons of each category vs. no 
effect (no-intercept model) and each category vs. another category (intercept model). 
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Publication bias 
Funnel plots of effect sizes against standard errors for outcomes with >10 studies7 were 
examined for asymmetry, with Egger’s bias test10 used as a corresponding statistical test 
with p<.10 indicating asymmetry. If asymmetry is a result of a lack of small studies with 
small effects, this can indicate possible publication bias, and we computed a revised effect 
size estimate using the trim and fill method9.  
 
Analyses were performed using the metafor30 and robumeta11 packages in R. 
Data availability 
Data will be made available to qualified investigators upon request to the corresponding 
author. 
RESULTS 
Study selection and data characteristics 
Study inclusion  
4,903 unique hits were identified through database searches. Initial screening of 
titles/abstracts identified 131 potentially eligible articles, reduced to 70 eligible articles 
following full text review (Figure 1). Rater agreement for study selection was high (90% 
agreement). 
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Participant characteristics 
A total of N=1069 participants comprised the aggregated data, with n=994 receiving NMDA 
medication and n=971 a control procedure. As crossover designs were primarily used, study 
biological sex composition (reported by k=65 of 70 studies; M=72.3% male) and age (k=45; 
M= 28.2 years, SD=6.2) were closely equivalent for NMDA and control conditions. Twenty-
one studies reported bodyweight (M=74.0kg).  
Study characteristics 
Study locations were Denmark (k=16), Germany (k=8), USA (k=9), Sweden (k=7), 
Netherlands (k=6), Norway (k=4), UK (k=4), France (k=3), Japan (k=3), Canada (k=2), Finland 
(k=2), South Korea (k=2), Switzerland (k=2), Australia (k=1) and Brazil/France (k=1). 
Medication/control was administered using a repeated-measures crossover (k=64) or 
parallel independent-groups (k=6) design, with most studies (k=54) also recording baseline 
pain responses. All 70 articles were published in peer reviewed journals and are 
summarised in Table 1 (available from Dryad: https://doi.org/10.5061/dryad.sm4tj6tX). 
NMDAR antagonists 
There were 54 ketamine (racemic k=41, S(+)-ketamine k=12, both=1) and 12 
dextromethorphan studies with several other antagonists each examined by a single study. 
For acute noxious stimulation (without previous hyperalgesic induction), medication was 
administered pre-emptively (k=52) and/or during (k=26) noxious stimulation. For 
hyperalgesic inductions, medication was initiated pre-emptively (k=24) and/or during 
(k=16) hyperalgesia. For pre-emptive administration, oral compounds were administered so 
that pain assessment occurred before the drug’s half-life period had been reached. 
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Delivery methods and dosage. Ketamine was delivered through IV (k=43), intramuscular 
(k=4), oral (k=3) or subcutaneous (k=3) routes or as a topical gel (k=1). Mean ketamine 
dosage (k=49) was 0.34 mg/kg (range=0.03 – 1.00), with similar mean dosages used for 
racemic (M=0.33 mg/kg, range=0.06 - 1.00) and S(+)-ketamine (M=0.39 mg/kg, range=0.03-
0.95). IV infusions were delivered with (k=29) or without (k=12) an initial bolus dose or this 
could not be determined (k=3), with a mean infusion time of 36 mins (range=1-150 mins). 
Dextromethorphan was administered in oral (k=11) and IV (k=1) form with a mean dosage 
of 0.92 mg/kg (range=0.17–2.71 mg/kg).  
66 studies used a placebo and 4 studies used a baseline control. For the placebo, 64 studies 
used an inactive compound and 2 used diphenhydramine, which exhibits ketamine-like 
sedative effects without analgesia32. 
Pain induction methods and outcomes  
Noxious stimuli were applied to areas of primary (k=33) or secondary (k=24) hyperalgesia or 
unsensitized areas (k=66). Hyperalgesia was most commonly induced with capsaicin  
applied for 15-60 mins (k=16) or a 7-min heat burn (k=13) in accordance with common 
protocols. Pain outcomes were intensity (k=56), usually 0-10 ratings, threshold (k=35), size 
of secondary hyperalgesic area (k=22), tolerance (k=12) and/or affective pain ratings (k=6). 
Several experimental pain inductions were used across upper and lower body sites (see 
Table 1). Acute pain stimuli were typically brief (0-5 mins), with principal exceptions of 
ischemic (M=24 mins) and capsaicin (M=29 mins). 
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Outliers 
Large externally studentized residuals29 (>3.0) suggested one possible outlier for 
hyperalgesic area (ref e-33 in Appendix 4, available from Dryad: 
https://doi.org/10.5061/dryad.sm4tj6tX) and two for pain intensity (ref e-33 and e-38 in 
Appendix 4). Scrutiny of the data and methodology from these studies did not reveal any 
identifiable study anomalies. Nevertheless, given the small number of outliers these cases 
were removed, with sensitivity analysis conducted to determine the effect of their removal. 
Quality of evidence 
Good agreement (>90%) was found across raters for study validity items, with 
disagreement resolved after consultation with a third reviewer. Validity ratings (Appendix 
3) and study characteristics described previously suggested common use of sound 
methodological practices. Most studies used randomization (86%), at least single (90%) or 
double (81%) blinding, and were placebo-controlled (94%), with 67% studies using 
randomized placebo-controlled double-blind designs. Crossover studies reported a washout 
period of >=1 (typically 7) days (88%), with 10% not providing data and 2% reporting <1-day 
washout. Fewer than 50% of studies provided details on any pre-existing pain, analgesic use 
or the population from which participants were recruited. However, the predominant use 
of crossover designs (91%) may largely obviate the possibility that analgesic effects are 
attributable to differences in group characteristics. 
Meta-analysis: Primary outcomes 
As racemic ketamine and S(+)-ketamine demonstrated consistently larger effect sizes than 
dextromethorphan (see ‘Drug type, dosage and hyperalgesic state’ subsection), analysis of 
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pooled data was not considered appropriate, and separate meta-analyses were conducted 
for each of these antagonists. Six different NMDAR antagonists were only assessed by a 
single study (see data in Table 1 available from Dryad: 
https://doi.org/10.5061/dryad.sm4tj6tX). As this is insufficient data for individual meta-
analyses of these antagonists, they were not included in further analyses of pain outcomes. 
Pain affect was not examined as an outcome as initial analysis produced an adjusted df<427. 
Pain intensity ratings 
A forest plot of effect sizes for 54 studies of pain intensity is presented in Figure 2. Detailed 
results of meta-analyses are presented in Table 2 and show analgesic effects for racemic 
ketamine (SMD=0.57, p<.001) and S(+)-ketamine (SMD=0.69, p=.001) but not 
dextromethorphan (SMD=0.07, p=.59). Moderate-high variability in effect size for ketamine 
agents was observed (I2=67-70%, τ2=0.15-0.19) but direction of effects consistently 
indicated analgesia.  
To obtain the magnitude of ketamine effects in the original 0-10 pain rating units, we 
repeated analyses using unstandardized pain ratings where available (k=42). As a direct 
comparison of racemic ketamine and S(+)-ketamine found no differences in effect size 
(p=0.54), we collapsed these into a single ketamine category to maximize power. Results 
indicated that average pain ratings were 1.2 points (CI95[0.88, 1.44], p<.001) lower for 
ketamine (M=3.4) compared to control (M=4.6), a reduction of 26%. The heterogeneity 
statistic τ indicated that the average magnitude of different analgesic effects in the 
population was likely to vary between a -0.41 and 2.72 mean points reduction. 
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For remaining pain outcomes, ketamine and S(+)-ketamine data were collapsed into a 
single ketamine category as there were relatively few studies of S(+)-ketamine for these 
outcomes (hyperalgesia k=1, tolerance k=3), and little difference in their mean effect sizes 
(maximum SMD difference=.12). 
 
Area of hyperalgesia 
Ketamine (racemic and S(+)-ketamine enantiomers combined) produced a moderate 
reduction in the size of the area of secondary hyperalgesia (k=15; SMD=0.54, CI95[0.34, 
0.74], p<.001). Moderate variation in the magnitude of effect size was observed (I2=46%, 
τ2=0.07), but with all studies indicating a reduction in pain area. No effects of 
dextromethorphan were found (k=4, SMD=0.21, CI95[-0.31, 0.73], p=.73). 
Pain tolerance 
Ketamine resulted in moderately increased pain tolerance (k=9; SMD=0.46, CI95[0.19, 0.72], 
p=.004), with direction of effects in all studies consistent with analgesia but with moderate 
inconsistency in size of effect (I2=60%, τ2=0.08) observed. No meta-analysis was performed 
for dextromethorphan as only one study of pain tolerance was available. 
Meta-analysis: Secondary outcomes 
Pain threshold  
A small increase in pain threshold was found following ketamine administration (k=30; 
SMD=0.31, CI95[0.17, 0.45], p<.001), with all studies indicating analgesia but with high 
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inconsistency in effect size (I2=72%, τ2=0.13). There were too few studies of 
dextromethorphan and pain threshold for reliable analysis (adjusted df<4). 
Side effects  
Side effects (SEs) of NMDAR antagonists were assessed by 48 studies, 37 of which reported 
incidence. Assessment method was often unreported, but some studies stated use of 
standard checklists or recording of spontaneously-reported effects. Incidence was 
computed for studies where SEs were reported by at least 5 studies and were: sedation 
(k=8; 70% of participants), feeling of drunkenness (k=7; 58%), dizziness (k=23; 57%), 
drowsiness (k=5; 56%), out-of-body sensations (k=5; 54%), paresthesia (k=10; 37%), and 
nausea (k=15; 19%). Nearly all studies reported side effects were mild. SEs on the placebo 
arm were occasionally assessed with no SEs generally reported. 
While these statistics provide an indication of common SEs, likely bias in incidence values 
should caution against their interpretation as representative of true incidences and 
prompted us not to conduct meta-analysis on SEs. Specifically, studies often did not report 
a priori which SEs were assessed and often stated that only commonly occurring symptoms 
were reported. This is likely to upwardly bias estimates, as omission of unreported low 
incidences would artificially increase average incidence. 
Publication bias 
Funnel plots and Egger's test for ketamine (collapsed across enantiomers to maximize 
power) indicated asymmetry (p’s<.01) for pain intensity (Figure 3) and hyperalgesic area  
consistent with possible publication bias. Trim and fill estimates resulted in smaller 
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estimated effects for ketamine for both pain intensity ratings (SMD=0.48 from 0.58) and 
hyperalgesic area (SMD=0.37 from 0.54). 
Meta-regression: Primary moderators 
Meta-regression was performed for the pain intensity outcome only, as adjusted df was 
largely <4 for other outcomes. Although previous analyses showed no effects of 
dextromethorphan, we included this in meta-regression to provide preliminary information 
on whether any effects might exist but be affected by potential moderators. When 
examining dose-response relationship, we included antagonist type in the same analysis to 
control for differences across antagonists in dosage. Only oral and IV routes were included 
in dose-response analysis so that a common, standardized mg/kg metric could be used.  
Drug type, dosage and hyperalgesic state 
Meta-regression results indicated larger effect sizes for racemic ketamine (k=31; difference 
(Δ) in SMD =+.50, p=.006) and S(+)-ketamine (k=11; ΔSMD=+.62, p=.008) compared to 
dextromethorphan. No association of dosage with effect size was found (k=43; p=.20) as 
illustrated in Figure 4 (dose x drug interaction terms were also included to explore whether 
any dose-response relationship varied with drug type, but no statistically significant effects 
were found, p>.65). For hyperalgesic state, slightly smaller analgesic effects were observed 
for secondary hyperalgesic (k=10; ΔSMD=-0.21) and primary hyperalgesic (k=14; ΔSMD=-
0.14) inductions compared to acute testing (without hyperalgesia), but these differences 
were not statistically significant (p’s=.24-.39). 
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Meta-regression: Secondary moderators 
Meta-regression of pain intensity was performed separately for each secondary moderator 
of noxious stimulus type (k=51), drug timing (k=51), sex composition (k=49), testing site 
(k=51), IV infusion period and pain duration (k=51) coded as tonic (typically 20-30 mins) and 
phasic (0-5 mins). No statistically significant effects were found for any secondary 
moderators (p’s=.22-.92). 
Sensitivity analysis 
The effect of various data decisions on results were examined by repeating analyses (a) 
replacing the estimated value of r=0.65 between outcomes with alternative correlations 
(r’s=0.40-0.90), (b) excluding studies where extraction decisions described in the Method 
section (Data Extraction subsection) were made, and (c) not removing outliers. We also 
reran all meta-analyses using only randomized double-blind placebo-controlled trials. Little 
change in effect size was found for all reanalysis, with a maximum SMD change of 0.12 
observed (indicating an increased SMD for pain tolerance). 
DISCUSSION 
Meta-analysis of 70 controlled experimental pain trials, totaling 1069 participants and 
consisting mostly of randomized double-blind designs, provided robust evidence for 
analgesic effects of low-dose ketamine. Key findings were: (1) ketamine produced a 
moderate decrease in pain, with estimated effects slightly diminished after accounting for 
possible publication bias; (2) racemic ketamine (SMD=0.57) and S(+)-ketamine (SMD=0.69) 
produced similar analgesia; (3) dextromethorphan did not reliably produce analgesia; (4) 
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pain relief was observed for both short-term acute pain and in hyperalgesic models; and (5) 
side effects (e.g. sedation, sensory disturbance) were common but mild at the relatively 
low doses used.  
 
Low-dose ketamine (0.03–1.00 mg/kg) decreased mean pain intensity ratings from 4.6 to 
3.4 on a 0-10 scale, a reduction of 1.2 points or 26%. This is broadly consistent with a 
recent meta-analysis of 9 trials of surgical patients that found a decrease of 1cm on a 10cm 
VAS for ketamine used as an adjunctive analgesic3. The mean 1.2-point pain reduction that 
we observed across 42 experimental ketamine trials approaches the median decrease of 
1.4 points or 23% identified by a recent meta-analysis21 as indicating minimum clinically 
important change. However, the same meta-analysis found that a median decrease of 3.2 
points (a 57% reduction) was needed for substantial clinically important pain relief, and the 
reduction we found here for ketamine would seem unlikely to be recognized as offering 
major improvement in pain. Considerable heterogeneity in effect size was also observed, 
indicating that ketamine analgesia is likely to be inconsistent across individuals or 
conditions, although no reliable modifiers of effect were identified from the available data 
(but are likely to include differences in the ability to metabolize ketamine). Overall, while 
findings from a large number of trials strongly support the pain-relieving effects of 
subanesthetic doses of ketamine, these effects were modest. This suggests that ketamine 
could be most useful when opioids are contraindicated, when a very rapid onset of action is 
required, or as a molecular basis for the future development of more potent and refined 
NMDAR medications. 
 
A comparison of the analgesic potency of racemic ketamine, S(+)-ketamine and 
dextromethorphan found that, despite the greater NMDA receptor affinity of S(+)-
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ketamine6, there was limited evidence of a superior analgesic effect compared to racemic 
ketamine. Moreover, both types of ketamine exhibited analgesic effects where 
dextromethorphan did not. The apparently selective effects of ketamine could help guide 
the identification of key cellular properties fundamentally involved in analgesia, such as 
differing affinities for specific binding sites across different NMDAR antagonists26. 
Alternatively, dextromethorphan may have been ineffective due to insufficient dosages for 
analgesia (although these were nearly 3 times higher than ketamine). Even if dosages were 
inadequate, however, the risk of exacerbating side effects at higher dosages might prove 
prohibitive in all but the most refractory cases and emphasizes the need for refinement of 
existing NMDAR antagonists if there is any hope of their routine use as pain medication.  
 
One of the primary therapeutic mechanisms of ketamine is believed to reversal of central 
sensitization, via the NMDAR-mediated suppression of neuronal hyperexcitability that 
occurs during persistent pain states and leads to hyperalgesia6. Interestingly, current 
findings identified ketamine as similarly effective for reducing both acute pain and 
hyperalgesia. As acute pain activates primary afferent C fibers and these fibers synapse 
onto the wide dynamic range neurons involved in central sensitization, this suggests that 
inhibition of NMDARs in this area also affects the processing of acute nociceptive signals. 
Alternatively, ketamine acts on numerous other pathways including muscarinic, 
monoaminergic and (at high dosages) μ-opioid receptors, although these are generally 
believed to less likely candidates for ketamine’s analgesic effects23. While our current 
understanding of complex structures of NMDARs in humans is limited, these findings 
appear to provide reliable evidence of significant NMDAR involvement in both acute and 
hyperalgesic pain processes.  
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Evidence of ketamine analgesia in acute and hyperalgesic models (which mimic central 
sensitization in chronic pain), suggests a basis for the development of more refined NMDAR 
antagonists for management of both acute and chronic pain. If such antagonists can be 
sufficiently refined to isolate analgesic from adverse effects, this might lead to the 
development of a new class of routinely used pain medication as alternatives to existing 
treatments. As cellular mechanisms of action of NMDAR antagonists are different to 
opioids, they may provide potentially effective treatment for refractory pain resistant to 
conventional opioid treatment.  In addition, there is little current consensus on optimal 
dosage within subanesthetic range (up to 1mg/kg) 14. The current finding suggests that 
dosing at lower end of range may be preferable to higher doses in achieving similar 
analgesic effects while minimizing adverse reactions. The current findings also demonstrate 
that human experimental pain models are sensitive to the analgesic effects of NMDAR 
antagonists and thus provide a useful means of enquiry where stimulus parameters can be 
carefully manipulated to provide insights into underlying mechanisms.  
 
The current meta-analysis has limitations. First, while experimental models of acute pain 
and hyperalgesia avoid many of the confounds present in clinical data and can reliably 
replicate key pathological features of acute and chronic pain, they do not capture the 
entire range of experience of a multifactorial pain condition. In addition, NMDAR 
antagonists may offer the potential for longer-term clinical pain reduction through gradual 
changes in neuroplasticity, that would not be captured by short-term testing. Second, 
although most study designs were double-blind RCTs, overt side effects may rule out true 
blinding. Although some control conditions included medications with ketamine-like side 
effects and found similar analgesia, active placebo effects cannot be dismissed.  
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Given the potential for abuse, hepatotoxicity and other side effects of ketamine at high 
doses23, there is an obvious need for the development of NMDAR antagonists that 
selectively target analgesia, which may involve activation of specific protein subunits22. 
Experimental selective NMDAR antagonists such as AV-10131 and GV19677133 have 
unfortunately met with limited success, but research is still at a preliminary stage. Given 
the considerable variation in the analgesic effects of ketamine across different studies, it is 
also important for research to identify for whom and under what conditions pain relief is 
likely to be optimal.  
 
We found robust evidence that low-dose ketamine (up to 1mg/kg), but not 
dextromethorphan, reduces acute pain and hyperalgesia. Dose-response curves also 
suggests ketamine may be just as effective when administered at the lower end of the 
subanesthetic dose range. However, pain relief was only modest, and if this translates to 
similarly modest effects for clinical pain, the most useful application of ketamine for pain 
could be when opioids are contraindicated, rapid analgesia is required, or pain is resistant 
to conventional medication. Nevertheless, there is still much that is unknown on the 
mechanisms of NMDAR antagonists and future pharmacokinetic development may lead to 
a more refined and potent analgesic.  
  
THOMPSON   
 
23 
Appendix 1. Author contributions. 
Name Location Role Contribution 
Trevor 
Thompson, PhD  
University of Greenwich, 
London, UK 
Author study design and 
conceptualization, data 
extraction, analysis and 
interpretation, drafting 
manuscript  
Fiona Whiter, 
PhD 
York Health Economics 
Consortium, York, UK 
Author study selection, data 
extraction, quality 
assessment 
Katy Gallop, MSc  
 
Acaster-Lloyd Health  
Outcomes Consulting, 
London, UK 
Author study selection, data 
extraction, quality 
assessment 
Nicola  
Veronese, MD 
National Research Council, 
Padova, Italy 
Author critical revision of manuscript 
for intellectual content 
 
Marco Solmi, MD University of Padova, 
Padova, Italy 
Author critical revision of manuscript 
for intellectual content 
 
Paul Newton, PhD University of Greenwich, 
London, UK 
Author critical revision of manuscript 
for intellectual content 
Brendon Stubbs, 
PhD 
Institute of Psychiatry, 
Psychology & 
Neuroscience, King's 
College London, UK 
Author interpretation of data, critical 
revision of manuscript for 
intellectual content 
  
THOMPSON   
 
24 
REFERENCES 
1. Aiyer R, Mehta N, Gungor S, Gulati A. A systematic review of NMDA receptor 
antagonists for treatment of neuropathic pain in clinical practice. Clin J Pain 
2018;34:450-467 
2. Arendt-Nielsen L, Nielsen J, Petersen-Felix S, Schnider TW, Zbinden AM. Effect of 
racemic mixture and the (S+)-isomer of ketamine on temporal and spatial summation 
of pain. Br J Anaesth 1996;77:625-631 
3. Assouline B, Tramèr MR, Kreienbühl L, Elia N. Benefit and harm of adding ketamine to 
an opioid in a patient-controlled analgesia device for the control of postoperative 
pain: systematic review and meta-analyses of randomized controlled trials with trial 
sequential analyses. Pain 2016;157:2854-2864 
4. Bell RF, Kalso EA. Ketamine for pain management. PAIN Reports 2018;3:e674 
5. Chizh BA, Priestley T, Rowbotham M, Schaffler K. Predicting therapeutic efficacy - 
experimental pain in human subjects. Brain Res Rev 2009;60:243-254 
6. Cohen SP et al. Consensus guidelines on the use of intravenous ketamine infusions for 
chronic pain from the American society of regional anesthesia and pain medicine, the 
American academy of pain medicine, and the American society of anesthesiologists. 
Reg Anesth Pain Med 2018;43:521-546 
7. Cooper H, Hedges L, Valentine J. Handbook of research synthesis and meta-analysis. 
NY: Russell Sage Foundation; 2009. 
8. Duong S, Bravo D, Todd KJ, Finlayson RJ, Tran DQ. Treatment of complex regional pain 
syndrome: an updated systematic review and narrative synthesis. Can J Anaesth 
2018;65:658-684 
THOMPSON   
 
25 
9. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and 
adjusting for publication bias in meta-analysis. Biometrics 2000;56:455-463 
10. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a 
simple, graphical test. BMJ 1997;315:629-634 
11. Fisher Z, Tipton E, Zhipeng H. robumeta: Robust variance meta-regression. R package 
version 2.0. 2017 
12. Graven-Nielsen T, Segerdahl M, Svensson P, Arendt-Nielsen L. Methods for induction 
and assessment of pain in humans with clinical and pharmacological examples. In: 
Kruger L, ed: Methods in pain research. FL, CRC Press, 2001, pp 264-304 
13. Hedges LV, Tipton E, Johnson MC. Robust variance estimation in meta-regression with 
dependent effect size estimates. Res Synth Methods 2010;1:39-65 
14. Jonkman K, Dahan A, Van De Donk T, Aarts L, Niesters M, Van Velzen M. Ketamine for 
pain. F1000Res 2017;6 
15. Karlow N et al. A Systematic Review and Meta-analysis of Ketamine as an Alternative 
to Opioids for Acute Pain in the Emergency Department. Acad Emerg Med 
2018;25:1086-1097 
16. Kuiken SD, Van Den Berg SJ, Tytgat GN, Boeckxstaens GE. Oral S(+)-ketamine does not 
change visceral perception in health. Dig Dis Sci 2004;49:1745-1751 
17. Michelet D et al. Ketamine for chronic non-cancer pain: A meta-analysis and trial 
sequential analysis of randomized controlled trials. Eur J Pain 2018;22:632-646 
18. Moher D et al. Preferred reporting items for systematic review and meta-analysis 
protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1-9 
19. Moore A, Derry S, Eccleston C, Kalso E. Expect analgesic failure; pursue analgesic 
success. BMJ 2013;346:1-6 
THOMPSON   
 
26 
20. Morris SB, Deshon RP. Combining effect size estimates in meta-analysis with repeated 
measures and independent-groups designs. Psychol Methods 2002;7:105-125 
21. Olsen MF et al. Pain relief that matters to patients: systematic review of empirical 
studies assessing the minimum clinically important difference in acute pain. BMC Med 
2017;15:35 
22. Petrenko AB, Yamakura T, Baba H, Shimoji K. The role of N-methyl-D-aspartate 
(NMDA) receptors in pain: a review. Anesth Analg 2003;97:1108-1116 
23. Schwenk ES et al. Consensus guidelines on the use of intravenous ketamine infusions 
for acute pain management from the American society of regional anesthesia and 
pain medicine, the American academy of pain medicine, and the American society of 
anesthesiologists. Reg Anesth Pain Med 2018;43:456-466 
24. Sigtermans M et al. S(+)-ketamine effect on experimental pain and cardiac output: a 
population pharmacokinetic-pharmacodynamic modeling study in healthy volunteers. 
Anesthesiology 2009;111:892-903 
25. Sleigh J, Harvey M, Voss L, Denny B. Ketamine – More mechanisms of action than just 
NMDA blockade. Trends in Anaesthesia and Critical Care 2014;4:76-81 
26. Smith HS, Wymer JP, Sang CN. Glutamate receptor antagonists. In: Smith HS, ed: 
Current therapy in pain. PA, USA, Elsevier, 2009, pp 480-488 
27. Tanner-Smith EE, Tipton E. Robust variance estimation with dependent effect sizes: 
practical considerations including a software tutorial in Stata and spss. Res Synth 
Methods 2014;5:13-30 
28. Thompson T, Oram C, Correll CU, Tsermentseli S, Stubbs B. Analgesic effects of 
alcohol: a systematic review and meta-analysis of controlled experimental studies in 
healthy participants. J Pain 2017;18:499-510 
THOMPSON   
 
27 
29. Viechtbauer W, Cheung MW. Outlier and influence diagnostics for meta-analysis. Res 
Synth Methods 2010;1:112-125 
30. Viechtbauer W. Metafor: meta-analysis package for R. R package version 
2010;2010:1-0 
31. Wallace M, White A, Grako KA, Lane R, Cato AJ, Snodgrass HR. Randomized, double-
blind, placebo-controlled, dose-escalation study: Investigation of the safety, 
pharmacokinetics, and antihyperalgesic activity of l-4-chlorokynurenine in healthy 
volunteers. Scand J Pain 2017;17:243-251 
32. Wallace MS, Ridgeway BIII, Leung A, Schulteis G, Yaksh TL. Concentration-effect 
relationships for intravenous alfentanil and ketamine infusions in human volunteers: 
effects on acute thresholds and capsaicin-evoked hyperpathia. J Clin Pharmacol 
2002;42:70-80 
33. Wallace MS et al. A randomized, double-blind, placebo-controlled trial of a glycine 
antagonist in neuropathic pain. Neurology 2002;59:1694-1700 
34. Willert RP, Woolf CJ, Hobson AR, Delaney C, Thompson DG, Aziz Q. The development 
and maintenance of human visceral pain hypersensitivity is dependent on the N-
methyl-D-aspartate receptor. Gastroenterology 2004;126: 683-692 
35. Worlddata.info: Average sizes of men and women. 2018. 
https://www.worlddata.info/average-bodyheight.php 
  
THOMPSON   
 
28 
LIST OF FIGURES 
Figure 1. PRISMA flowchart. 
Figure 2. Forest plot of Standardized Mean Differences (SMDs) for pain ratings across 54 
studies, with summary SMDs for racemic ketamine, S(+)-ketamine and dextromethorphan 
based on random-effects meta-analysis (effect sizes from single studies of other 
medications shown for comparative purposes) 
Figure 3. Funnel plot of standardized mean differences (SMDs) from 42 studies of ketamine 
and pain intensity (filled circles) and 7 estimated SMDs (empty circles) assumed to be 
missing due to publication bias. 
Figure 4. No dose-response relationship for pain ratings for S(+)-ketamine, racemic 
ketamine or dextromethorphan.  
LIST OF TABLES 
Table 1. Characteristics of studies included in meta-analysis (available from Dryad: 
https://doi.org/10.5061/dryad.sm4tj6tX). 
Table 2. Meta-analysis of pain intensity ratings and aggregated study characteristics for 
three different NMDAR antagonists. 
APPENDICES  
Appendix 1. Author contributions. 
Appendix 2. Search strategy (available from Dryad:https://doi.org/10.5061/dryad.sm4tj6tX) 
Appendix 3. Study validity criteria (available from Dryad: 
https://doi.org/10.5061/dryad.sm4tj6tX). 
THOMPSON   
 
29 
Appendix 4. References of studies included in meta-analysis (available from Dryad: 
https://doi.org/10.5061/dryad.sm4tj6tX).
THOMPSON 28 
 
 
 
 
 
 
30 
Table 2. Meta-analysis of pain intensity ratings and aggregated study characteristics for three different NMDAR antagonists. 
 
 
SMD 95% CI p Number 
of studies 
Number of 
participants 
I2 τ2 Mean dose 
mg/kg 
Primary delivery route 
(number of studies) 
Mean age / 
proportion of males 
Racemic ketamine 0.57  0.40,  0.74 <.001 31 508 70 .15 0.39  Intravenous (23/31) 28 yrs / 70% 
S(+)-Ketamine 0.69  0.35,  1.03 .001 11 123 67 .19 0.37  Intravenous (10/11) 27 yrs/ 74% 
Dextromethorphan 0.07 -0.21,  0.34 .591 10 132 53 .09 0.95 Oral (10/10) 32 yrs / 74% 
SMD=standardized mean difference; 95% CI=95% confidence interval 
 
 Records identified through 
database searching 
(n = 6,835) 
Sc
re
en
in
g 
In
clu
de
d 
El
ig
ib
ili
ty
 
Id
en
tif
ica
tio
n 
Additional records identified 
through other sources 
(n = 5 ) 
Records after duplicates removed 
(n = 4,903) 
Records screened 
(n = 4,903) 
Records excluded 
(n = 4,772) 
Full-text articles assessed 
for eligibility 
(n =131) 
Full-text articles excluded 
(n =61) 
Ineligible intervention (n=15) 
No pain outcome (n=13) 
Ineligible population (n=13) 
Not an empirical study (n=8) 
No response to data request (n=5) 
Authors not contactable (n=4)  
Ineligible control comparator (n=3) 
Studies included in 
qualitative synthesis 
(n = 70) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 70) 
   
   
   
   
3.2%
3.5%
3.6%
2.7%
4.3%
2.3%
3.7%
3.8%
4.6%
4.6%
3.9%
4.0%
3.4%
3.4%
2.9%
3.4%
4.2%
3.1%
3.2%
2.1%
3.0%
3.4%
3.6%
3.1%
3.1%
3.5%
2.6%
2.3%
1.9%
2.2%
1.2%
 9.8%
 9.8%
10.3%
10.6%
10.5%
 9.4%
 9.8%
 9.3%
10.9%
 7.7%
 1.9%
 7.0%
 6.5%
11.2%
11.3%
15.5%
 8.8%
11.2%
14.4%
 6.6%
 7.6%
Weight
Ketamine
S(+)−ketamine
Dextromethorphan
Summary
SMD
Ref e−14
Ref e−25
Ref e−61
Ref e−28
Ref e−50
Ref e−23
Ref e−11
Ref e−48
Ref e−26
Ref e−18
Ref e−31
Ref e−34
Ref e−58
Ref e−43
Ref e−4
Ref e−42
Ref e−45
Ref e−60
Ref e−6
Ref e−35
Ref e−30
Ref e−39
Ref e−57
Ref e−32
Ref e−49
Ref e−56
Ref e−8
 Ref e−4
Ref e−66
Ref e−3
Ref e−54
Ref e−63
Ref e−21
Ref e−46
 Ref e−48
Ref e−9
Ref e−5
Ref e−51
Ref e−62
Ref e−27
Ref e−24
Ref e−2
Ref e−1
Ref e−10
Ref e−47
Ref e−7
Ref e−59
Ref e−41
Ref e−16
Ref e−65
Ref e−55
Ref e−19
Ref e−52
Ref e−29
Ref e−37
Ref e−64
−2 0 2 4
favours control            favours drug
NMDAR antagonist
L−4 chlorokynurenine
CHF3381
Neramexane
Magnesium sulphate
Ketamine
S(+)−ketamine
Dextromethorphan
Pain Intensity
Standardised Mean Difference
 (Pain Intensity Ratings)
St
an
da
rd
 E
rro
r
1.
12
8
0.
84
6
0.
56
4
0.
28
2
0
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
−2 −1 0 1 2 3
(2.71 mg kg)
Dextromethorphan
Ketamine
S(+)−Ketamine
0.0 0.5 1.0 1.5
−1.0
−0.5
0.0
0.5
1.0
1.5
2.0
−1.0
−0.5
0.0
0.5
1.0
1.5
2.0
−1.0
−0.5
0.0
0.5
1.0
1.5
2.0
Dosage mg/kg
SM
D
